1 Momentum Stock Worth Your Attention Today and 2 We Choose to Overlook

Stocks Near Their Yearly Peaks

All the stocks discussed here are currently trading close to their highest prices in the past year. This typically signals positive momentum, which may be driven by successful product launches, favorable shifts in their industries, or stronger financial results.

Although strong momentum can sometimes predict future gains, it doesn't always guarantee lasting performance and has led investors astray in the past. With that in mind, we highlight one stock worth your attention and two that are better avoided.

Stocks to Consider Selling

Ziff Davis (ZD)

Monthly Performance: +31.8%

Ziff Davis (NASDAQ:ZD), established in 1927 and known for PC Magazine, now manages a collection of digital media and subscription brands spanning technology, e-commerce, gaming, healthcare, and cybersecurity.

Reasons ZD May Underperform:

• Its offerings are struggling in current markets, as evidenced by stagnant sales over the past five years.
• Profitability has declined, with earnings per share dropping an average of 4.1% annually in the same period.
• The company has become more capital-intensive, with its free cash flow margin shrinking by 9.3 percentage points over five years.

ZD is priced at $42.36 per share, trading at a forward P/E of 6.2.

Archer-Daniels-Midland (ADM)

Monthly Performance: -0.4%

Archer-Daniels-Midland (NYSE:ADM) specializes in processing and transporting agricultural commodities such as grains and oilseeds, and produces ingredients for food, beverages, animal feed, and industrial uses.

Why We’re Not Favoring ADM:

• Sales have declined by 7.5% annually over the last three years, indicating unfavorable consumer trends.
• Low gross margins of 6.5% reflect the challenges of commoditized products, poor unit economics, and intense competition.
• Earnings per share have fallen by 24.2% annually in the past three years, which is concerning since stock prices often follow EPS trends over time.

ADM currently trades at $67.05 per share with a forward P/E of 16.5.

Stock Worth Watching

AbbVie (ABBV)

Monthly Performance: +2.8%

AbbVie (NYSE:ABBV), formed from Abbott Laboratories’ pharmaceutical division in 2013, is a biopharma company focused on developing and marketing treatments for autoimmune disorders, cancer, neurological conditions, and other complex diseases.

Why ABBV Stands Out:

• Its massive revenue of $61.16 billion provides significant scale and regulatory advantages over newer competitors.
• A strong free cash flow margin of 36.3% gives the company flexibility in how it uses its capital.
• Exceptional returns on capital highlight management’s ability to identify and grow highly profitable ventures.

AbbVie’s share price of $229.50 equates to a forward P/E of 15.9. Wondering if it’s the right time to invest?

Top-Quality Stocks for Any Market

WHILE YOU’RE HERE: Discover 9 Stocks That Consistently Outperform. The best-performing stocks don’t just beat the market once—they do it repeatedly. They feature strong revenue growth, expanding free cash flow, and superior returns on capital that set them apart from competitors. These companies have already been recognized by the market.

Our AI-driven platform suggests there’s still room for growth. Find out which nine stocks made the list this week—absolutely free.

Past picks include well-known names like Nvidia, which soared 1,326% from June 2020 to June 2025, and lesser-known companies such as Exlservice, which delivered a 354% return over five years.